Ignite Creation Date:
2025-12-24 @ 10:19 PM
Ignite Modification Date:
2025-12-25 @ 7:52 PM
Study NCT ID:
NCT04660435
Status:
RECRUITING
Last Update Posted:
2025-02-26
First Post:
2020-12-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Mandatory: formalin fixed and paraffin embedded (FFPE) tumor block from a baseline biopsy of a metastatic site taken before starting treatment Optional: material from an archival FFPE tumor block from the primary breast tumor Optional: material from one FFPE tumor block of a tissue biopsy from a metastatic site collected upon disease progression to first-line treatment with CDK4/6 inhibitor and AI 24 mL of blood will be collected in EDTA tubes at each time-point Additional 6 ml of whole blood will be collected in EDTA tubes only at baseline'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 150}, 'targetDuration': '5 Years', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-09-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2026-12-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-02-25', 'studyFirstSubmitDate': '2020-12-03', 'studyFirstSubmitQcDate': '2020-12-03', 'lastUpdatePostDateStruct': {'date': '2025-02-26', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-12-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression free survival', 'timeFrame': '5 years', 'description': 'time from inclusion date to date of first documentation of progression or death due to any cause, whichever occurs first'}], 'secondaryOutcomes': [{'measure': 'Clinical benefit rate', 'timeFrame': '5 years', 'description': 'Complete Response, Partial Response, or Stable Disease ≥24 weeks'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['CDK 4/6 inhibitors', 'Thymidine Kinase', 'Palbociclib', 'Abemaciclib', 'Ribociclib', 'circulating tumour DNA', 'gene expression signatures', 'aromatase inhibitors'], 'conditions': ['Metastatic Breast Cancer', 'ER Positive Breast Cancer', 'HER2-negative Breast Cancer']}, 'referencesModule': {'references': [{'pmid': '35172272', 'type': 'BACKGROUND', 'citation': 'Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM; International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022 Mar;164:39-51. doi: 10.1016/j.ejca.2021.12.030. Epub 2022 Feb 13.'}]}, 'descriptionModule': {'briefSummary': 'This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor as per standard clinical practice.\n\nBlood and tissue samples will be collected for biomarker analysis, including thymidine kinase1 activity, gene expression signatures and circulating tumor DNA.', 'detailedDescription': 'Enrolled patients will receive first-line treatment with a CDK4/6 inhibitor + AI (anastrozole, letrozole or exemestane) in accordance with local practice. No drugs will be provided by the study Sponsor. Following disease progression on first-line therapy, subsequent, second-line therapy will be administered at physician discretion and as per physician choice.\n\nFor all participating patients, serum and plasma samples will be collected at the following time-points:\n\n* Baseline (\\< 2 weeks before treatment)\n* During treatment with CDK4/6 inhibitors + AI: at day 15 (+/- 2) of the first cycle, day 1 (+/-2) of cycle 2, day 1 (+/- 2) of the cycle closest to the first trial-mandated tumor evaluation (after 12-18 weeks from study inclusion), day 1 (+/- 2) of cycle 6, and every 6 cycles thereafter\n* At disease progression or permanent discontinuation of CDK4/6 inhibitors + AI (within 35 days from last CDK4/6 inhibitor dosing)\n* During the immediate subsequent treatment (second line) (any type, as per physician choice): at day 1 (+/- 2) of cycle 1 (if \\> 7 days from last CDK4/6 inhibitors dosing), at day 1 of cycles 3, 6 and every 6 cycles thereafter\n* At disease progression or permanent discontinuation of second line treatment (within 35 days from last dosing)\n\nOne sample of whole blood will be collected at baseline.\n\nAll blood samples will be taken concomitantly with blood draws for routine clinical practice.\n\nTo be eligible for the study, availability of material from one formalin fixed and paraffin embedded (FFPE) tumor block from a baseline biopsy of a metastatic site taken before starting treatment is mandatory. Although not mandatory for inclusion, material from an archival FFPE tumor block from the primary breast tumor must also be provided, whenever available. Additionally, material from one FFPE tumor block of a tissue biopsy from a metastatic site collected upon disease progression to first-line treatment with CDK4/6 in and AI will be collected whenever possible'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'genderBased': True, 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'Pre- and post-menopausal patients with luminal (ER-positive and HER2-negative) MBC who have not received prior systemic therapy for MBC, who are candidate to first-line treatment with an aromatase inhibitor and a CDK4/6i as per standard clinical practice.\n\nPatients must have evaluable disease according to RECIST 1.1 (either measurable or non-measurable). Patients with bone-only disease will be allowed in a specific sub-cohort, which will comprise 10% of the total sample size.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Women aged 18 years or older, with a diagnosis of metastatic breast cancer\n2. ER-positive and HER2-negative disease as assessed locally either on primary tumor tissue or on a biopsy of a metastasis\n3. The patient has not received any prior systemic therapy for metastatic breast cancer (may have received prior hormonal therapy or chemotherapy in the neo/adjuvant setting)\n4. The patient is candidate to receive first-line therapy with an aromatase inhibitor (AI) and a CDK4/6 inhibitor per local clinical practice\n5. The patient must have evaluable disease according to RECIST 1.1 (either measurable or non-measurable).\n\n Note: Patients with bone-only disease will be allowed in a specific sub-cohort, which will comprise 10% of the total sample size.\n6. Hystologic material from one formalin-fixed, paraffin-embedded (FFPE) tumor block from a diagnostic core or excisional biopsy of a metastatic lesion, taken before study entry must be provided (patients with bone-only disease will be accepted into the trial without a biopsy of the metastatic site). Hystologic material from an additional biopsy (core or excisional) taken at time of disease progression on the study treatment must also be provided, if clinically feasible. When available, hystologic material from an FFPE tumor block from the primary breast cancer must also be submitted.\n7. The patient agrees to provide blood samples. at the trial specified time points\n\nExclusion Criteria:\n\n1. Patients with metastatic disease isolated to the central nervous system (CNS) without metastatic involvement of any other site, unless surgical excision of CNS metastasis has been performed and the tumor tissue is available for the study.\n2. Previous or current non-breast malignancies within the last 5 years, with the exception of in situ carcinoma of the cervix and/or adequately treated basal cell or squamous cell carcinoma of the skin'}, 'identificationModule': {'nctId': 'NCT04660435', 'acronym': 'TIRESIAS', 'briefTitle': 'To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Fondazione Sandro Pitigliani'}, 'officialTitle': 'Identification and Monitoring of Resistance to First-line Treatment with CDK 4/6 Inhibitors in Combination with Aromatase Inhibitors in Patients with Metastatic Luminal Breast Cancer Through Non-invasive Biomarkers', 'orgStudyIdInfo': {'id': 'Tiresias'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Women with ER+/Her2 negative metastatic breast cancer', 'description': 'Patients with ER+/HER2-negative metastatic breast cancer candidate to first-line treatment with a CDK4/6 inhibitor and an aromatase inhibitor as per standard clinical practice', 'interventionNames': ['Diagnostic Test: Thymidine kinase activity']}], 'interventions': [{'name': 'Thymidine kinase activity', 'type': 'DIAGNOSTIC_TEST', 'otherNames': ['Divitum'], 'description': 'DiviTum® assay determines the enzymatic activity of TK in serum samples', 'armGroupLabels': ['Women with ER+/Her2 negative metastatic breast cancer']}]}, 'contactsLocationsModule': {'locations': [{'zip': '59100', 'city': 'Prato', 'state': 'Tuscany', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Luca Malorni', 'role': 'CONTACT', 'email': 'luca.malorni@uslcentro.toscana.it', 'phone': '+390574802523'}], 'facility': 'Hospital Santo Stefano', 'geoPoint': {'lat': 43.8805, 'lon': 11.09699}}], 'centralContacts': [{'name': 'Luca Malorni', 'role': 'CONTACT', 'email': 'luca.malorni@uslcentro.toscana.it', 'phone': '+390574802523'}, {'name': 'Chiara Biagioni', 'role': 'CONTACT', 'email': 'chiara.biagioni@uslcentro.toscana.it', 'phone': '+390574802526'}], 'overallOfficials': [{'name': 'Luca Malorni', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Azienda USL Toscana Centro - Prato'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fondazione Sandro Pitigliani', 'class': 'OTHER'}, 'collaborators': [{'name': 'Clinical Research Technology S.r.l.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}